The weekly litigation news digest is live. Subscribe now

Pharmaceutical Oral Dosage Forms Comprising Dabigatran Etexilate And Its Pharmaceutically Acceptable Salts

Patent No. EP2588090 (titled "Pharmaceutical Oral Dosage Forms Comprising Dabigatran Etexilate And Its Pharmaceutically Acceptable Salts") was filed by Krka on Jul 1, 2011. The application was issued on Nov 22, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
EDERJan 19, 2018EDER
GEORG KALHAMMERSTEPHAN TEIPELJan 19, 2018-
GENERICS UKJan 16, 2018ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2588090

KRKA
Application Number
EP11732405A
Filing Date
Jul 1, 2011
Status
Patent Maintained As Amended
Oct 20, 2023
Publication Date
Nov 22, 2023